CRISPR/CAS9-MEDIATED SILENCING OF SHP-1 SIGNIFICANTLY ENHANCES THE ANTI-GLIOMA ACTIVITY OF IL-13RA2 CAR T CELLS

被引：2
|
作者：
Petersen, Christopher [1 ]
Bell, Matthew [1 ]
Houke, Haley [1 ]
Yi, Zongzhen [1 ]
Gottschalk, Stephen [1 ]
Krenciute, Giedre [1 ]
机构：
[1] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
10.1093/neuonc/noz036.134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IMMU-13
引用
收藏
页码：95 / 96
页数：2
相关论文
共 21 条
  • [1] CRISPR/Cas9-Mediated Ablation of the SHP-1 Gene Enhances the Therapeutic Efficacy of IL-13Ra2 CAR T Cells in Glioma Xenograft Models
    Thomas, Christopher
    Bell, Petersen Matthew
    Houke, Haley
    Gottschalk, Stephen
    Krenciute, Giedre
    MOLECULAR THERAPY, 2019, 27 (04) : 319 - 319
  • [2] CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro
    Liu, Ming
    Zhang, Linlin
    Zhong, Mingtian
    Long, Yihao
    Yang, Wenhui
    Liu, Ting
    Huang, Xingxu
    Ma, Xiaodong
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [3] CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro
    Ming Liu
    Linlin Zhang
    Mingtian Zhong
    Yihao Long
    Wenhui Yang
    Ting Liu
    Xingxu Huang
    Xiaodong Ma
    Experimental Hematology & Oncology, 12
  • [4] Screening and anti-glioma activity of Chiloscyllium plagiosum anti-human IL-13Ra2 single-domain antibody
    Qin, Lanyi
    Ren, Qingyu
    Lu, Chaoling
    Zhu, Tianci
    Lu, Yijun
    Chen, Shuangxing
    Tong, Shuna
    Jiang, Xiaofeng
    Lyu, Zhengbing
    IMMUNOLOGY, 2023, 170 (01) : 105 - 119
  • [5] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
    Rupp, Levi J.
    Schumann, Kathrin
    Roybal, Kole T.
    Gate, Rachel E.
    Ye, Chun J.
    Lim, Wendell A.
    Marson, Alexander
    SCIENTIFIC REPORTS, 2017, 7
  • [6] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
    Levi J. Rupp
    Kathrin Schumann
    Kole T. Roybal
    Rachel E. Gate
    Chun J. Ye
    Wendell A. Lim
    Alexander Marson
    Scientific Reports, 7
  • [7] CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
    Wanghong Hu
    Zhenguo Zi
    Yanling Jin
    Gaoxin Li
    Kang Shao
    Qiliang Cai
    Xiaojing Ma
    Fang Wei
    Cancer Immunology, Immunotherapy, 2019, 68 : 365 - 377
  • [8] CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
    Hu, Wanghong
    Zi, Zhenguo
    Jin, Yanling
    Li, Gaoxin
    Shao, Kang
    Cai, Qiliang
    Ma, Xiaojing
    Wei, Fang
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (03) : 365 - 377
  • [9] CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro
    Khadijeh Alishah
    Matthias Birtel
    Elham Masoumi
    Leila Jafarzadeh
    Hamid Reza Mirzaee
    Jamshid Hadjati
    Ralf-Holger Voss
    Mustafa Diken
    Sedighe Asad
    Journal of Translational Medicine, 19
  • [10] CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro
    Alishah, Khadijeh
    Birtel, Matthias
    Masoumi, Elham
    Jafarzadeh, Leila
    Mirzaee, Hamid Reza
    Hadjati, Jamshid
    Voss, Ralf-Holger
    Diken, Mustafa
    Asad, Sedighe
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
123